Pharmacological properties of parenteral cephalosporins: Rationale for ambulatory use

Drugs

Volumn 59, Issue SUPPL. 3, 2000, Pages 9-18

  Strehl, Egid ^a   Kees, Frieder ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFALORIDINE; CEFALOTIN; CEFAMANDOLE; CEFAZOLIN; CEFEPIME; CEFMENOXIME; CEFMETAZOLE; CEFODIZIME; CEFONICID; CEFOPERAZONE; CEFOTAXIME; CEFOTETAN; CEFOTIAM; CEFOXITIN; CEFPIROME; CEFTAZIDIME; CEFTIZOXIME; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; CEPHALOSPORINASE; CEPHAMYCIN; FLOMOXEF; LATAMOXEF; QUINOLONE DERIVATIVE;

AMBULATORY CARE; BACTERIUM; BLOOD DISEASE; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INDUCTION; HUMAN; INFECTION; NONHUMAN; REVIEW;

EID: 0033939083     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059003-00002     Document Type: Review

References (46)

1. Williams JD. Classification of cephalosporins. Drugs 1987; 34 Suppl. 2: 15-22
2. Bryskier A, Aszodi J, Chantot JF. Parenteral cephalosporin classification. Exp Opin Invest Drugs 1994; 3: 145-71
3. Klein NC, Cunha BA. The selection and use of cephalosporins: a review. Adv Ther 1995; 12: 83-101
4. Simon C, Stille W. Cephalosporine. In: Simon C, Stille W, editors. Antibiotikatherapie in Klinik und Praxis. Stuttgart, New York: Schattauer, 1997: 69-112
5. Williams JD, Moosdeen F. In vitro antibacterial effects of cephalosporins. Drugs 1987; 34 Suppl. 2: 44-63
6. Bryan JP. Cephalosporins and carbapenems. Curr Opin Infect Dis 1991; 4: 727-41
7. Neu HC. Structure-activity relationships: biological. In Page MI, editor. The chemistry of ß-lactams. London: Blackie Academic & Professional, 1992: 103-28
8. Strehl E. Struktur-Wirkungsvergleiche bei parenteralen Cephalosporinen und Carbapenemen. Krankenhauspharmazie 1996; 17: 285-9
9. Adu A, Armour CL. Drug utilisation review (DUR) of the third generation cephalosporins. Drugs 1995; 50: 423-39
10. Kalman D, Barriere SL. Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins. Tex Heart Inst J 1990; 17: 203-15
11. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med 1990; 88: 38-44
12. Kayser FH. Basic aspects of antibiotic resistance in the multiresistant staphylococcus: an overview. Chemotherapy 1996; 42 Suppl. 2: 2-12
13. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. An update. Drug Saf 1993; 9: 132-42
14. Livermore DM. Mechanisms of resistance to cephalosporin antibiotics. Drugs 1987; 34 Suppl. 2: 64-88
15. Cunha BA. Third-generation cephalosporins: a review. Clin Ther 1992; 14: 616-52
16. Klein N, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995; 79: 705-19
17. Cherubin CE, Eng RHK, Norrby R, et al. Penetration of newer cephalosporins into cerebrospinal fluid. Rev Infect Dis 1989; 11: 526-48
18. Wise R. Tissue penetration of the fourth generation parenteral cephalosporins. J Chemother 1996; 8 Suppl. 2: 63-72
19. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96
20. Outpatient parenteral antibiotic therapy. Management of serious infections. Part I: medical, socioeconomic, and legal issues. Symposium proceedings. Sonoma, California, Jan 26-27, 1993. Hosp Pract Off Ed 1993; 28 Suppl. 1: 5-64
21. Outpatient parenteral antibiotic therapy. Management of serious infections. Part II: Amenable infections and models for delivery. Symposium proceedings. Sonoma, California, Jan 26-27, 1993. Hosp Pract Off Ed 1993; 28 Suppl. 2: 1-64
22. Benet LZ, Phie S, Schwartz JB. Design and optimization of dosage regimens: pharmacokinetic data. In: Goodman & Gilman, editors. The pharmacological basis of therapeutics. New York: McGraw-Hill, 1996: 1707-92
23. Stöckel K. Pharmakokinetik parenteraler Cephalosporine in Prüfphase III. Fortschr Antimicrob Antineopl Chemother 1982; 1: 105-13
24. Christ W. Pharmacological properties of cephalosporins. Infection 1991; 19 Suppl. 5: 244-52
25. Brockmeier D, Dagrosa EE. Pharmacokinetic profile of cefodizime. Infection 1992; 20 Suppl. 1: S14-S17
26. Conte Jr JE. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function. J Clin Pharmacol 1994; 34: 1066-70
27. Barriere SL, Hatheway GJ, Gambertoglio JG, et al. Pharmacokinetics of cefonicid, a new broad-spectrum cephalosporum. Antimicrob Agents Chemother 1982; 21 (6): 935-8
28. Rockowitz J, Tunkel AR. Bacterial meningitis. Drugs 1995; 50: 838-53
29. Neu HC. Cephalosporins in the treatment of meningitis. Drugs 1987; 34 Suppl. 2: 135-53
30. Ter Braak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycoside plus beta-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58-66
31. Francioli P, Ruch W, Stamboulian D. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicenter study. Clin Infect Dis 1995; 21: 1406-10
32. Baskin MN, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. J Pediatr 1992; 120: 22-7
33. Bergan T. Pharmacokinetic properties of the cephalosporins. Drugs 1987; 34 Suppl. 2: 89-104
34. Klepser ME, Marangos MN, Patel KB, et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharmacokinet 1995; 28: 361-84
35. Yuk-Choi JH, Nightingale CH, Williams Jr TW. Considerations in dosage selection for third generation cephalosporins. Clin Pharmacokinet 1992; 22: 132-43
36. Patel IH, Sugihara JG, Weinfeld RE, et al. Ceftriaxone pharmacokinetics in patients with various degrees of renal impairment. Antimicrob Agents Chemother 1984; 25: 438-42
37. Ti TY, Fortin L, Kreeft JH, et al. Kinetic disposition of intravenous ceftriaxone in normal subjects and patients with renal failure on hemodialysis or peritoneal dialysis. Antimicrob Agents Chemother 1984; 25: 83-7
38. Cohen D, Appel GB, Scully B, et al. Pharmacokinetics of ceftriaxone in patients with renal failure and in those undergoing haemodialysis. Antimicrob Agents Chemother 1984; 24: 529-32
39. Neu HC. Third generation cephalosporins: safety profiles after in years of clinical use. J Clin Pharmacol 1990; 30: 396-403
40. Kumana CR, Yuen KY. Parenteral aminoglycoside therapy. Drugs 1994; 47: 902-13
41. Nathwani D. Outpatient treatment with teicoplanin. Chemotherapie J 1996; 5 Suppl. 1: 35-8
42. Marra F, Partovi N, Jewesson P. Aminoglycoside administration as a single daily dose. Drugs 1996; 52: 344-70
43. Rybak MJ, McGrath BJ. Combination antimicrobial therapy for bacterial infections. Drugs 1996; 52: 390-405
44. Mauceri AA, HIAT Study Group. Treatment of bone and joint infections utilising a third-generation cephalosporin with an outpatient drug delivery device. Am J Med 1994; 97 Suppl. 2A: 14-22
45. Mustafa MM, Aquino VM, Pappo A, et al. A pilot study of outpatient management of febrile neutropenic children with cancer at low risk of bacteremia. J Pediatr 1996; 128: 847-9
46. Poretz DM, HIAT Study Group. Treatment of skin and soft-tissue infections utilising an outpatient parenteral drug delivery device: a multicenter trial. Am J Med 1994; 97 Suppl. 2A: 23-7